Given the ability of OP to increase E-cadherin expression and decrease N-cadherin and VE-cadherin expression as previously reported by us [22], ovarian cancer treated with this drug may become more adherent to the surrounding tissue and not metastasize as our data indicate. The gene discussed is CDH2; the disease is ovarian carcinoma.